Member Info for Matml74

Page 39 outlines some details on diagnostics. Also plenty in this doc on cancer treatment and fast tracking the regulatory process.

Apparently detailed vision for diagnostics coming later this year.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1000030/life-sciences-vision.pdf

Yes will definitely get last patient dosed rns.

I think around end of August but hopefully sooner.

TMT,

Spot on with that post. A good example of this is has been with the CEO of Seeing Machines, who has worked hard at getting institutional investment out of the US and has been successful in getting two funds on board. Their significant buying moved the SP from 3/4p range to the 10/12p range increasing the MCAP 250 million and stabilised the SP dramatically and created a base to build on with further news.

I am sure Sean will do the same here over the next 12 months.

There are some seriously deluded people on this board. Overnight the testing space for LFD's disappeared. Pull the other one. The rns for detection of delta variant was a week a go FFS and EU approval less than a month.

Abbott still expecting sales of $4b-$4.5b in rapid covid testing in 2021.

Do not be fooled by those people who come on this board for the first time trying to convince you otherwise.

They are just trading the stock.

Totally. They will move on soon enough. LSE really needs to sort that **** out!

Bull****. Volume is tiny.

Yes noted that as well. Not long to wait at all. I remember this time last year knowing we would get the initial MRE in Q4 and that came around in no time.

Folks would be crazy to sell before the FS IMO.

Massive over reaction Chippy. People always expect too much from these types of presentations. I thought SD was fine and dropped a few little hints. I also thought his comments on the SP were spot on. As many have said ignore the day to day movements, which unfortunately many on here can't or don't want to do.

Thankfully it was done out of trading hours or this BB would have been a ****fight and the mm's would have crashed the price.

Thanks Matterhorn.

120UT but I hear ya!

Looking forward to Q4 results at the end of the month.

Yes new CEO has been rubbish. Just sits around (on his hands) drinking Little Creatures Pale Ales all day waiting for Sandeep to call and report some new drills.

Really wish he would do something about the share price. Thats his job isn't it!

Southwest,

Lots of sensible points there but I do disagree on your last sentence. There is no reason why GGP can’t 10 bag in the future it just depends on the timeframe you are looking at. It is certainly unlikely to happen in a 12 month period as it did in 2020 but the future here is very bright. The current CEO’s previous company saw exceptional growth over a 6/7 year period. In a year or two’s time GGP will be asset/cash rich and has a CEO that knows how to utilise assists to grow a company into a top 100 ASX miner.

I expect him to do the same here and the returns will be exceptional. Just a matter of patience.

Well that’s not true is it. The SP was approx 24p when he started. The scallywag results were released under GH’s watch and it’s been his selling down of shares that haven’t helped the SP.

Agree totally DGR. The CEO's job is to ensure the company is moving forward and creating value and to my mind he is doing this well at present. SD has done a number of interviews since his appointment so there has been plenty of communication. There was also the Investor presentation on the GGP website released in April. The CEO's job is not to appease shareholders concerns over SP drops. If he is spending any time doing that he is not doing his job properly.

Its just LSE site being ****. It is on the official RNS still.

https://www.londonstockexchange.com/news-article/AVCT/affidx-lateral-flow-test-detects-delta-variant/15036340

No LFD’s can detect what covid strain you have. PCR rest don’t even detect all strains or what strain you have. Genome sequencing is how you know what variant you have.

Just one other thing regarding drug manufacturing. Progression to P3 Activ 2 should come with a preorder and this would be the trigger to start larger scale manufacturing. You would expect this to come over the next month or so based on what we know from Castro’s comments.

Matterhorn,

I hear what you are saying. It is a guessing game for us at present unfortunately. I am of the belief that the company will be doing everything in its power to get this drug approved prior to next winter, either through EUA stemming from Activ-2 or completion of the P3 with readout in the Autumn.

Having spent 15 years developing this drug I can't see an interim readout happening when the full dataset would be available within months of it. As the board has highlighted, data is king and IMO the company won't risk it being compromised by an early readout.

Here is a paper on interim readouts which outlines both sides of the argument. Even if there was an interim the DMC would be the only one privy to the data and the case for stopping the trial early would need to be very strong.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703711/